Efficacy and Safety of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in Patients With HER2-positive Resectable Gastric or Gastr-oesophageal Junction Carcinoma (GC/EGJ) -- a Prospective, Single-arm, Phase II Study
Latest Information Update: 02 Jul 2024
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Jun 2024 Results(Between Oct 2022 and June 2023, n=32 patients ) focusing on the perioperative immunotherapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Oct 2023 Preliminary Results (n=18) assessing Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer presented at the 48th European Society for Medical Oncology Congress
- 06 Jun 2023 Preliminary results (n=12; From September 13, 2021 to February 01, 2023) assessing the efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.